Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis
Authors:
Open Access
- 10 September 2019
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (9) , 1-18
Abstract
Dysregulation of PML, a significant tumor suppressor is linked with cancers of different histological origins, with a decreased expression observed with a higher tumor grade. This necessitates studying the mechanisms to maintain a stable expression of PML. However much less is known about the transcriptional regulation of PML, more so in the context of breast carcinoma. ERβ has emerged as a critical factor in understanding breast cancer, especially since a huge proportion of breast cancers are ERα− and thus insensitive to tamoxifen therapy. This study aims to uncover an unidentified mechanism of PML gene regulation and its stabilization in breast cancer via ERβ signalling and the impact on cellular apoptosis. We found that clinical expression of PML positively correlates with that of ERβ both in normal and breast carcinoma samples and inversely correlates with markers of cellular proliferation, hinting towards a possible mechanistic interdependence. Both mRNA and protein expression of PML were increased in response to ERβ overexpression on multiple human breast cancer cell lines. Mechanistically, luciferase reporter assays and chromatin-immunoprecipitation assays demonstrated that ERβ can interact with the PML promoter via ERE and AP1 sites to enhance its transcription. ERβ induced stable PML expression causes a decline of its target protein Survivin and simultaneously provides a stable docking platform leading to stabilisation of its target Foxo3a, further causing transcriptional upregulation of pro-apoptotic factors p21 and p27. Immunohistochemical analyses of cancer and normal breast tissues and functional assays conducted corroborated the findings. Collectively, our study identifies ERβ signalling as a novel mechanism for PML gene regulation in ERα− breast cancer. It also reveals bi-directional downstream effect in which ‘ERβ-PML-(Foxo3a/Survivin)’ network acts as a therapeutic axis by suppressing cellular survival and promoting cellular apoptosis in breast carcinoma.Keywords
This publication has 61 references indexed in Scilit:
- Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinomaMolecular Oncology, 2018
- Estrogen receptor alpha transcriptionally activates casein kinase 2 alpha: A pivotal regulator of promyelocytic leukaemia protein (PML) and AKT in oncogenesisCellular Signalling, 2016
- HAUSP regulates c-MYC expression via de-ubiquitination of TRRAPCellular Oncology, 2015
- Estrogen receptor beta in breast cancerMolecular and Cellular Endocrinology, 2014
- ERβ1 Represses FOXM1 Expression through Targeting ERα to Control Cell Proliferation in Breast CancerThe American Journal of Pathology, 2011
- Liganded and unliganded activation of estrogen receptor and hormone replacement therapiesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason GradingCancer Cell, 2010
- A CK2-Dependent Mechanism for Degradation of the PML Tumor SuppressorCell, 2006
- Differential subcellular distribution of estrogen receptor isoforms: Localization of ERα in the nucleoli and ERβ in the mitochondria of human osteosarcoma SaOS-2 and hepatocarcinoma HepG2 cell linesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2005
- The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancerBest Practice & Research Clinical Endocrinology & Metabolism, 2004